The Big Fight

  • by: |
  • 04/08/2013

On Saturday I was a panelist on the highly rated Indian public affairs television program, “The Big Fight.” The topic, the Indian Supreme Court’s ruling against Novartis and Gleevec.

My fellow panelists included an attorney from Ranbaxy, a representative from Novartis, an activist from Doctor’s Without Borders (MSF), a financial journalist, and a representative of the Indian pharmaceutical industry.

And it was, indeed, a big fight.

Expertly moderated by Vikram Chandra (one of India’s most respected journalists), the topics ranged from innovation to access to domestic industrial policy.

Mr. Chandra asked me if big multinational pharmaceutical companies made too much money. My response was that I didn’t know what “too much” meant – but that it was a good thing that most company profits are reinvested in R&D.

What I didn’t have time to say was that, as far as “excess profit” goes, that question is a lot more relevant to Indian drug manufacturers. Their profits last year were much higher than any innovator company. At Dr. Reddy’s net profits are up 88%. At Lupin profits are up 67%. And, at Sun Pharmaceuticals profit after taxes for the last year was 39%.

And while we’re in the pot calling the kettle black department, consider the claim by MSF India that access is the key issue. Really?

Less than 10% of India's CVD patients get even the most common medicines like diuretics and statins. Yet there are 10,500 licensed Indian drug manufacturers producing hundreds of generic anti-hypertensives and other CVD products on the market in India – very few of which reach India’s 45+ million diagnosed CVD patients.

The complete “Big Fight” can be found here.


Center for Medicine in the Public Interest is a nonprofit, non-partisan organization promoting innovative solutions that advance medical progress, reduce health disparities, extend life and make health care more affordable, preventive and patient-centered. CMPI also provides the public, policymakers and the media a reliable source of independent scientific analysis on issues ranging from personalized medicine, food and drug safety, health care reform and comparative effectiveness.

Blog Roll

Alliance for Patient Access Alternative Health Practice
Better Health
Biotech Blog
CA Medicine man
Cafe Pharma
Campaign for Modern Medicines
Carlat Psychiatry Blog
Clinical Psychology and Psychiatry: A Closer Look
Conservative's Forum
Club For Growth
Diabetes Mine
Disruptive Women
Doctors For Patient Care
Dr. Gov
Drug Channels
DTC Perspectives
Envisioning 2.0
FDA Law Blog
Fierce Pharma
Fresh Air Fund
Furious Seasons
Gel Health News
Hands Off My Health
Health Business Blog
Health Care BS
Health Care for All
Healthy Skepticism
Hooked: Ethics, Medicine, and Pharma
Hugh Hewitt
In the Pipeline
In Vivo
Internet Drug News
Jaz'd Healthcare
Jaz'd Pharmaceutical Industry
Jim Edwards' NRx
Kaus Files
Laffer Health Care Report
Little Green Footballs
Med Buzz
Media Research Center
More than Medicine
National Review
Neuroethics & Law
Nurses For Reform
Nurses For Reform Blog
Opinion Journal
Orange Book
Peter Rost
Pharm Aid
Pharma Blog Review
Pharma Blogsphere
Pharma Marketing Blog
Pharmacology Corner
Pharmaceutical Business Review
Piper Report
Prescription for a Cure
Public Plan Facts
Real Clear Politics
Shark Report
Shearlings Got Plowed
Taking Back America
Terra Sigillata
The Cycle
The Catalyst
The Lonely Conservative
Town Hall
Washington Monthly
World of DTC Marketing
WSJ Health Blog